Daily injections are a painful way of life for an estimated 3.7 million Americans who are insulin-dependent diabetics. The condition, characterized by high blood sugar levels that result from defects in the body’s ability to produce and/or use insulin, is the fifth leading cause of death by disease in the U.S., and can lead to severely debilitating or fatal complications, such as blindness, kidney disease, heart disease, and amputations.
Current treatments are effective in controlling the disease, but patient compliance is a very real concern because the available insulin delivery technologies are invasive and cause fear and pain. Most diabetic patients need to inject insulin multiple times in a day, which adds to the trauma. Pharmaceutical companies continue to work toward finding a way to improve insulin delivery, despite obstacles and past failures.
“Everybody is trying to be the first to introduce an alternative insulin delivery for the simple reason that there are millions of patients who depend on insulin every day and they are really tired of using needles,” says Ajit Baid, pharmaceutical industry…
The Future of Insulin: Selected Products in Development
Diabetes Market Facts
History of Diabetes
Experts on this topic
Ajit Baid. Industry Analyst, Pharmaceuticals, Frost & Sullivan, San Antonio; Frost & Sullivan provides strategic market consulting and training
Jonathan Eppstein. President of Research and Chief Technical Officer, Altea Development Corp., Tucker, Ga.; Altea is a private company whose goal is to develop breakthrough products for biotechnology drugs as well as pain medicines that serve the unmet medical and market needs to provide patient-friendly, noninvasive patch products for proteins and vaccines, and a rapid onset patch for pain medications
Melissa Feltmann. Spokesperson, Aventis Pharmaceuticals Inc., Bridgewater, N.J.; Aventis is a world leader in the discovery, development, and marketing of innovative pharmaceutical products
Michael M. Goldberg, M.D. Chairman and CEO, Emisphere Technologies Inc., Tarrytown, N.Y.; Emisphere is a biopharmaceutical company pioneering the oral delivery of otherwise injectable or inhaled drugs
Max Herrmann. Head of Pharmaceutical Research, ING Financial Markets, London; ING Financial Markets is a unit of ING Group, a global financial institution offering banking, insurance, and asset management to more than 50 million private, corporate, and institutional clients in 65 countries
Francine Ratner Kaufman, M.D. Professor of Pediatrics, Childrens Hospital Los Angeles, and president, American Diabetes Association, Alexandria, Va.; The American Diabetes Association is the nation’s leading nonprofit health organization providing diabetes research, information, and advocacy
Christopher H. Price, Ph.D. President and CEO, Nobex Corp., Research Triangle Park, N.C.; Nobex is a privately held, developmental-stage, drug-delivery company specializing in medicinal chemistry to improve the performance of therapeutic drugs
Evan D. Rosen, M.D., Ph.D. Assistant Professor of Medicine, Harvard Medical School, Boston, assistant professor of medicine, Beth Israel Deaconess Medical Center, Boston, and diabetes medical director, Veritas Medicine, Cambridge, Mass.; Veritas Medicine is an online health resource focused on improving patient access to clinical trials and information about therapies in development for serious medical conditions
Mads Krogsgaard Thomsen, D.V.M., Ph.D, D.Sc. Chief Science Officer and Executive VP, Novo Nordisk Pharmaceuticals?Inc., Princeton, N.J.; Novo Nordisk, the U.S. affiliate of Novo Nordisk AS, Copenhagen, Denmark, combines drug discovery with state-of-the-art technology to turn science into solutions for people with diabetes, people with hemophilia, and children with growth hormone deficiency